Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $335K | $1.98M | $3.97M | $4.74M | $258K | $3.07M | $2.50M | $933K | $371K | $12.6M |
| Revenue growth | — | 490.7% | 100.4% | 19.6% | -94.6% | 1089.9% | -18.5% | -62.7% | -60.2% | 3292.5% |
| Operating income | -$33.2M | -$41.7M | -$42.8M | -$63.2M | -$79.1M | -$88.0M | -$42.2M | $21.5M | -$73.4M | $6.31M |
| Operating margin | -9916.7% | -2108.6% | -1079.3% | -1333.1% | -30664.0% | -2865.5% | -1685.9% | 2302.4% | -19773.9% | 50.2% |
| Net income | -$25.5M | -$38.7M | -$41.7M | -$60.9M | -$78.3M | -$89.8M | -$46.4M | $22.8M | -$68.6M | $8.57M |
| Net margin | -7609.3% | -1957.7% | -1051.4% | -1284.3% | -30348.8% | -2925.1% | -1854.4% | 2444.4% | -18481.4% | 68.1% |
| EPS (diluted) | -$95.87 | -$17.82 | -$2.60 | -$3.35 | -$3.52 | -$2.91 | -$1.23 | $0.43 | -$1.27 | $0.15 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.0M | -$39.1M | -$39.6M | -$50.0M | -$85.9M | -$64.3M | -$7.73M | -$33.0M | -$23.4M | -$12.6M |
| Capital expenditures | $830K | $27.0K | $2.44M | $314K | $157K | — | — | — | — | — |
| Free cash flow | -$29.8M | -$39.1M | -$42.1M | -$50.3M | -$86.0M | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.3M | $87.3M | $34.1M | $29.7M | $85.2M | $113M | $109M | $76.3M | $52.9M | $40.3M |
| Total assets | $13.8M | $93.5M | $129M | $106M | $153M | $171M | $125M | $182M | $111M | $68.9M |
| Total liabilities | $7.41M | $8.52M | $13.2M | $31.5M | $21.4M | $82.8M | $48.9M | $75.5M | $64.4M | $9.90M |
| Shareholders' equity | -$45.4M | $84.6M | $116M | $74.6M | $132M | $88.3M | $75.9M | $107M | $46.1M | $59.0M |
| Retained earnings | -$45.4M | -$96.8M | -$139M | -$199M | -$278M | -$367M | -$414M | -$391M | -$460M | -$451M |
| Shares (wtd avg diluted) | — | 14.4M | 17.2M | 19.2M | 29.3M | 30.9M | 37.6M | 53.0M | 54.0M | 59.0M |
Every figure is extracted from Spero Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.